258P Goserelin for ovarian protection in premenopausal breast cancer patients receiving cyclophosphamide containing chemotherapy

Abstract

Globally, breast cancer is the most common female reproductive cancer. Although alkylating chemotherapy is a part of initial treatment in women with curable breast cancer. Premature ovrian insufficiency (POI) is a potential consequence of this treatment and can cause infertility. The current work assessed role of Goserelin in reducing risk of POI in such women. A prospective study was conducted in period between 2017 and 2019 and enrolled 150 women with histologically confirmed breast cancer. Those women were randomly subdivided into two equal groups; Goserelin group where women received chemotherapy regimens with Goserelin and control group where women received chemotherapy regimens without Goserelin. Both groups were followed for one year after end of chemotherapy to assess frequency of POI. Both groups had insignificant differences as regarding baseline data with exception of singnicantly higher negative hormonal receptor among study group. Hot flashes and headache were the most frequent adverse effects in both groups. 12 patients (16%) of Goserelin group and 22 (29%) of the control group developed POI with significant difference (P< 0.05). Median time to resumption of menses was significantly lower among study group in comparison to that control group (5.70 vs. 10.60 months; P= 0.03). Based on the current, older age increased risk to POI while negative hormonal receptors and addition of Goserelin were reducing the frequency of POI. Goserelin co-treatment with regimens of chemotherapy in premenopausal women with breast cancer could reduce the frequency of POI and preserve the fertility among those women.